A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Levis, M; Smith, BD; Beran, M; Baer, MR; Erba, HP; Cripe, L; Coutre, S; Advani, A; Perl, A; Devetten, M; Stuart, R; Tallman, MS; Brown, P; Tremmel, L; Small, D

Published Date

  • November 16, 2005

Published In

Volume / Issue

  • 106 / 11

Start / End Page

  • 121A - 121A

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 47th Annual Meeting of the American-Society-of-Hematology

Conference Location

  • Atlanta, GA

Conference Start Date

  • December 10, 2005

Conference End Date

  • December 13, 2005